Macrophage Pharma has an expanding pipeline of new chemical entity (NCE) assets leveraging the ESM™ targeting platform to shape macrophage biology in multiple diseases including cancer, liver injury, fibrosis and other autoimmune diseases where macrophages are centrally involved.
Product | Discovery | Hit to Lead | Pre-clinical | Phase 1 | Phase 2 |
---|---|---|---|---|---|
ESM™ p38MAPK inhibitor Cancer and inflammation |
|||||
ESM™-P13K/mTOR inhibitor Cancer and fibrosis |
|||||
ESM™-inflammasome inhibitor Liver disease NAFLD/NASH |
|||||
ESM™ immune kinase inhibitor Autoimmunity |